Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month […]
NovoCure Limited (NASDAQ:NVCR – Get Free Report) shares traded down 6.2% during trading on Tuesday . The stock traded as low as $21.64 and last traded at $21.71. 545,541 shares traded hands during trading, a decline of 59% from the average session volume of 1,346,685 shares. The stock had previously closed at $23.15. Analysts Set […]
Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024
Phase 3 METIS trial in brain metastases from non-small cell lung cancer met.